Status:
COMPLETED
Input of the Use of Indometacin in Gitelman Syndrome as Compared to Potassium Sparing Diuretics
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Gitelman Syndrome
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
Gitelman syndrome is a rare renal disease where the kidneys are unable to normally retain some salts (sodium, potassium and magnesium). Main consequences of these renal leaks of salts are a tendency t...
Detailed Description
Patients with received in random order 75mg/day indometacin (Chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed b...
Eligibility Criteria
Inclusion
- patients 18-60 yrs old, both sex, with genetically proven Gitelman's syndrome, under birth pill control for woman.
Exclusion
- counter-indication to treatment under study
- Other diuretic or NAIS treatments than amiloride, spironolactone, or indometacin
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT01146197
Start Date
February 1 2010
End Date
January 1 2013
Last Update
December 10 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Européen Georges Pompidou
Paris, France, 75015